What were the RSU-related share conversions reported?

Three code M transactions converting 1,174, 312, and 1,061 RSUs into Class A shares on 10/16/2025.

Ginkgo Bioworks (DNA) CFO Form 4: 1,312 shares sold; RSUs converted

Ginkgo Bioworks (DNA) filed a Form 4 for its CFO showing routine equity activity tied to RSU vesting.

Accepted by SEC EDGAR 10/21/2025 - 04:56 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ginkgo Bioworks (DNA) filed a Form 4 for its CFO showing routine equity activity tied to RSU vesting. On 10/16/2025, restricted stock units were converted to Class A shares via code M in three tranches: 1,174 shares, 312 shares, and 1,061 shares.

On 10/17/2025, the CFO sold 1,312 shares at $13.649 per share under code S to cover tax withholding related to these vestings, as permitted by the company’s equity plans. Following the transactions, the CFO directly beneficially owned 6,738 Class A shares.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Coen Steven P.

Role See remarks

Sold 1,312 shs ($18K)

Approx. gross sale proceeds $18K

Approx. exercise cost $0.00

Share of Position Sold 16.3%

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	1,312	$13.649	$18K
Exercise	Restricted Stock Units	1,174	$0.00	$0.00
Exercise	Restricted Stock Units	312	$0.00	$0.00
Exercise	Restricted Stock Units	1,061	$0.00	$0.00
Exercise	Class A Common Stock	1,174	$0.00	$0.00
Exercise	Class A Common Stock	312	$0.00	$0.00
Exercise	Class A Common Stock	1,061	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 16,763 contracts (Direct); Class A Common Stock — 6,738 shares (Direct)

Holdings Before and After: Restricted Stock Units, 19,310 to 16,763 contracts (Direct); Class A Common Stock, 5,503 to 6,738 shares (Direct)

Footnotes (5)

F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2. Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
F3. The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter.
F4. The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.
F5. The RSUs vest as follows: 25% vested on April 16, 2025; 25% vested on July 16, 2025; 25% vested on October 16, 2025; and 25% will vest on January 16, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ginkgo Bioworks (DNA) disclose in this Form 4?

RSU conversions to Class A shares on 10/16/2025 and a sale of 1,312 shares on 10/17/2025 to cover tax withholding.

How many shares were sold by the DNA CFO and at what price?

1,312 shares were sold at $13.649 per share.

What is the CFO’s beneficial ownership after these transactions?

6,738 Class A shares, held directly.

Why were shares sold on 10/17/2025?

To cover tax withholding obligations associated with RSU vesting, as noted in the filing’s explanation.

What vesting schedules were noted for the RSUs?

Schedules include 25% on May 1, 2024 then 36 monthly installments; 2/48ths on May 1, 2024 then 46 monthly installments; and four quarterly 25% tranches ending January 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coen Steven P.

(Last)

(First)

(Middle)

C/O GINKGO BIOWORKS HOLDINGS, INC.

27 DRYDOCK AVENUE

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	10/16/2025		M⁽¹⁾		1,174	A	⁽¹⁾	6,677	D
Class A Common Stock	10/16/2025		M⁽¹⁾		312	A	⁽¹⁾	6,989	D
Class A Common Stock	10/16/2025		M⁽¹⁾		1,061	A	⁽¹⁾	8,050	D
Class A Common Stock	10/17/2025		S⁽²⁾		1,312	D	$13.649	6,738	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	10/16/2025		M⁽¹⁾			1,174	⁽³⁾	⁽³⁾	Class A Common Stock	1,174	⁽¹⁾	11,166	D
Restricted Stock Units	⁽¹⁾	10/16/2025		M⁽¹⁾			312	⁽⁴⁾	⁽⁴⁾	Class A Common Stock	312	⁽¹⁾	4,535	D
Restricted Stock Units	⁽¹⁾	10/16/2025		M⁽¹⁾			1,061	⁽⁵⁾	⁽⁵⁾	Class A Common Stock	1,061	⁽¹⁾	1,062	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

3. The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter.

4. The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.

5. The RSUs vest as follows: 25% vested on April 16, 2025; 25% vested on July 16, 2025; 25% vested on October 16, 2025; and 25% will vest on January 16, 2026.

Remarks:

Chief Financial Officer

	/s/ Karen Tepichin, Attorney-in-Fact	10/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR